BCIQ Profiles

Company Profile Report

In its first broad deal, Repare leads BMS deeper into synthetic lethality

A discovery collaboration between Repare and BMS is the former’s first time deploying its platform outside its own pipeline, and the latter’s biggest move yet in synthetic lethality.

Repare Therapeutics Inc. announced Tuesday it will receive a $65 million upfront payment, including a $15 million equity investment, from Bristol Myers Squibb

Read the full 509 word article

How to gain access

Continue reading with a
two-week free trial.